Long-term tetrahydroaminoacridine treatment and quantitative EEG in Alzheimer's disease.
The development of therapies for Alzheimer's disease (AD) has focused on drugs designed to correct the loss of cholinergic function within the central nervous system. Quantitative EEG (qEEG) changes associated with AD consist of background slowing. One way to study the effects of cholinergic drugs may be through assessment of their qEEG effects. The aim of the current work was to evaluate the effect of long-term treatment with tetrahydroaminoacridine (THA) on qEEG in AD patients.
Kogan
E A
EA
EEG and Epilepsy Unit, Tel-Aviv University, Tel-Aviv, Israel.
Verchovsky
R G
RG
Neufeld
M Y
MY
Klimovitsky
S Sh
SSh
Treves
T A
TA
Korczyn
A D
AD
D000368:Aged; D000369:Aged, 80 and over; D000513:Alpha Rhythm / Q000187:drug effects; D000544:Alzheimer Disease / Q000188:drug therapy*; D001611:Beta Rhythm / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003700:Delta Rhythm / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D005583:Fourier Analysis; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D012815:Signal Processing, Computer-Assisted; D013619:Tacrine / Q000627:therapeutic use*; D013826:Theta Rhythm / Q000187:drug effects
D002800:Cholinesterase Inhibitors; D013619:Tacrine